Pharmsynthez (MOEX: LIFE)
Russia
· Delayed Price · Currency is RUB 4.505
+0.415 (10.15%)
At close: Jul 8, 2022
Pharmsynthez Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 344.17 | 379.67 | 438.33 | 371.66 | 291.07 | 349.39 | Upgrade
|
| Revenue Growth (YoY) | -18.91% | -13.38% | 17.94% | 27.68% | -16.69% | -51.38% | Upgrade
|
| Cost of Revenue | 270.13 | 295.21 | 280.94 | 211.74 | 262.41 | 263.84 | Upgrade
|
| Gross Profit | 74.05 | 84.46 | 157.39 | 159.92 | 28.66 | 85.55 | Upgrade
|
| Selling, General & Admin | 187.14 | 194.74 | 260.94 | 256.96 | 245.76 | 404.27 | Upgrade
|
| Research & Development | 8.66 | 16.8 | 54.18 | 46.02 | 5.77 | 69.6 | Upgrade
|
| Other Operating Expenses | -7.6 | -1.68 | -90.31 | -12.28 | -5.14 | -201.31 | Upgrade
|
| Operating Expenses | 188.18 | 210.42 | 384.94 | 307.28 | 246.39 | 272.56 | Upgrade
|
| Operating Income | -114.14 | -125.96 | -227.55 | -147.36 | -217.73 | -187.01 | Upgrade
|
| Interest Expense | -41.35 | -41.33 | -36.38 | -29.55 | -9.44 | -9.9 | Upgrade
|
| Interest & Investment Income | 1.95 | 0.1 | 3.04 | 2.26 | 1.83 | 0.47 | Upgrade
|
| Earnings From Equity Investments | -8.55 | -14.38 | -17.04 | -56.2 | -305.35 | -271.36 | Upgrade
|
| Currency Exchange Gain (Loss) | -121.37 | -8.58 | 18.69 | -104.71 | 84.56 | -82.29 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -56.43 | -0.05 | -0.4 | -0.58 | Upgrade
|
| EBT Excluding Unusual Items | -283.46 | -190.15 | -315.66 | -335.61 | -446.53 | -550.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | -5.13 | -19.49 | -388.56 | -196.11 | -1,577 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.69 | 0.92 | -29.18 | 4.51 | -4.89 | - | Upgrade
|
| Pretax Income | -305.94 | -208.72 | -733.4 | -527.21 | -2,029 | -550.66 | Upgrade
|
| Income Tax Expense | -2.28 | -1.22 | -35.85 | -2.4 | -217.13 | -132.96 | Upgrade
|
| Earnings From Continuing Operations | -303.66 | -207.49 | -697.55 | -524.81 | -1,812 | -417.7 | Upgrade
|
| Net Income | -303.66 | -207.49 | -697.55 | -524.81 | -1,812 | -417.7 | Upgrade
|
| Net Income to Common | -303.66 | -207.49 | -697.55 | -524.81 | -1,812 | -417.7 | Upgrade
|
| Shares Outstanding (Basic) | 299 | 301 | 301 | 301 | 301 | 301 | Upgrade
|
| Shares Outstanding (Diluted) | 299 | 301 | 301 | 301 | 301 | 301 | Upgrade
|
| Shares Change (YoY) | -1.60% | - | - | - | - | 9.01% | Upgrade
|
| EPS (Basic) | -1.01 | -0.69 | -2.32 | -1.74 | -6.02 | -1.39 | Upgrade
|
| EPS (Diluted) | -1.02 | -0.69 | -2.32 | -1.74 | -6.02 | -1.39 | Upgrade
|
| Free Cash Flow | -362.58 | -6.82 | -62.97 | -242.45 | -83.39 | -132.12 | Upgrade
|
| Free Cash Flow Per Share | -1.21 | -0.02 | -0.21 | -0.81 | -0.28 | -0.44 | Upgrade
|
| Gross Margin | 21.51% | 22.24% | 35.91% | 43.03% | 9.85% | 24.49% | Upgrade
|
| Operating Margin | -33.16% | -33.18% | -51.91% | -39.65% | -74.80% | -53.52% | Upgrade
|
| Profit Margin | -88.23% | -54.65% | -159.14% | -141.21% | -622.45% | -119.55% | Upgrade
|
| Free Cash Flow Margin | -105.35% | -1.80% | -14.37% | -65.23% | -28.65% | -37.81% | Upgrade
|
| EBITDA | -97.72 | -106.06 | -196.35 | -102.96 | -191.8 | -132.42 | Upgrade
|
| EBITDA Margin | -28.39% | -27.94% | -44.79% | -27.70% | -65.89% | -37.90% | Upgrade
|
| D&A For EBITDA | 16.41 | 19.9 | 31.2 | 44.4 | 25.94 | 54.59 | Upgrade
|
| EBIT | -114.14 | -125.96 | -227.55 | -147.36 | -217.73 | -187.01 | Upgrade
|
| EBIT Margin | -33.16% | -33.18% | -51.91% | -39.65% | -74.80% | -53.52% | Upgrade
|
| Advertising Expenses | - | 5.76 | 12.32 | 7.2 | 2.76 | 17.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.